In the Pipeline: Encorafenib and Binimetinib in BRAF-Mutated Melanoma

  H&O  What makes the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib a good combination for use in BRAF-mutated melanoma? KF  Like other combinations of […]